Parkman Healthcare Partners LLC Takes Position in Stoke Therapeutics, Inc. $STOK

Parkman Healthcare Partners LLC acquired a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 355,443 shares of the company’s stock, valued at approximately $11,630,000. Parkman Healthcare Partners LLC owned about 0.55% of Stoke Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. BlackRock Inc. purchased a new position in Stoke Therapeutics in the second quarter valued at $192,307,000. Janus Henderson Group PLC lifted its holdings in Stoke Therapeutics by 333.8% during the 4th quarter. Janus Henderson Group PLC now owns 1,450,933 shares of the company’s stock worth $46,031,000 after buying an additional 1,116,452 shares during the last quarter. State Street Corp lifted its holdings in Stoke Therapeutics by 75.2% during the 4th quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after buying an additional 1,072,176 shares during the last quarter. Corient Private Wealth LLC acquired a new position in shares of Stoke Therapeutics during the 2nd quarter worth about $7,489,000. Finally, Troluce Capital Advisors LLC acquired a new position in shares of Stoke Therapeutics during the 1st quarter worth about $21,255,000.

Insider Activity at Stoke Therapeutics

In related news, insider Barry Ticho sold 4,767 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total transaction of $152,687.01. Following the completion of the sale, the insider owned 25,655 shares in the company, valued at $821,729.65. This represents a 15.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Jonathan Allan sold 2,861 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total transaction of $91,637.83. Following the transaction, the general counsel directly owned 21,225 shares in the company, valued at $679,836.75. The trade was a 11.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 30,623 shares of company stock worth $953,765 in the last 90 days. 9.60% of the stock is owned by insiders.

Stoke Therapeutics Stock Up 0.1%

Shares of NASDAQ STOK opened at $32.32 on Tuesday. The business has a 50-day moving average price of $31.04 and a 200 day moving average price of $32.23. The stock has a market cap of $2.09 billion, a PE ratio of -9.68 and a beta of 1.20. Stoke Therapeutics, Inc. has a 52-week low of $18.00 and a 52-week high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.13). The firm had revenue of $9.32 million for the quarter, compared to analyst estimates of $4.89 million. Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%. Sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -3.5 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. BTIG Research reiterated a “buy” rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a report on Monday, May 11th. Chardan Capital restated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Wedbush upped their price target on Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. JPMorgan Chase & Co. assumed coverage on shares of Stoke Therapeutics in a research note on Friday. They issued an “overweight” rating and a $40.00 price target on the stock. Finally, The Goldman Sachs Group started coverage on shares of Stoke Therapeutics in a report on Monday, July 13th. They set a “buy” rating and a $44.00 price objective on the stock. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Stoke Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $44.25.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.